Valuation: Mabvax Therapeutics Holdings Inc

Market Cap 1.11M 952K 890K 814K 1.54M 106M 1.55M 10.54M 4.1M 53.4M 4.17M 4.08M 177M P/E 2016
-0.93x
P/E 2017 -0.25x
Enterprise Value 3.59M 3.08M 2.88M 2.63M 4.97M 344M 5.02M 34.08M 13.25M 173M 13.49M 13.19M 571M EV / Sales 2016
147x
EV / Sales 2017 -
Free-Float
92.02%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
+3.31%-3.53%+71.28%+104.57% 69.06B
+1.78%+1.15%+49.15%+87.55% 63.06B
+2.77%+24.73%+10.11%-1.63% 28.34B
+1.80%-1.88%-1.78%+477.11% 27.07B
+7.41%+13.08%+58.57%+17.04% 25.45B
+3.98%+4.33%+39.41%-14.69% 19.69B
+1.02%+5.67%+273.94%+420.34% 19.19B
+0.10%+0.19%+12.19%+550.31% 15.95B
+2.77%+5.62%+48.03%+155.13% 13.52B
Average +2.75%+3.94%+62.32%+199.53% 31.26B
Weighted average by Cap. +2.80%+2.95%+59.10%+158.89%

Financials

2016 2017
Net sales 148K 127K 119K 109K 205K 14.18M 207K 1.4M 546K 7.12M 556K 544K 23.55M -
Net income -17.66M -15.14M -14.16M -12.94M -24.43M -1.69B -24.69M -168M -65.15M -849M -66.31M -64.87M -2.81B -19.02M -16.3M -15.25M -13.94M -26.31M -1.82B -26.59M -180M -70.17M -915M -71.42M -69.87M -3.03B
Net Debt 470K 403K 377K 345K 650K 45.01M 657K 4.46M 1.73M 22.6M 1.77M 1.73M 74.79M 2.48M 2.13M 1.99M 1.82M 3.43M 238M 3.47M 23.54M 9.15M 119M 9.32M 9.11M 395M
Logo Mabvax Therapeutics Holdings Inc
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer and pancreatitis. The Company discovered a pipeline of human monoclonal antibody product candidates based on the immune responses generated by patients. The Company's product pipeline includes ImmunoPET Imaging (MVT-2163) and Radioimmunotherapy (MVT-1075). MVT-2163 is an imaging agent for pancreatic cancer. MVT-1075 is a radioimmunotherapy for pancreatic cancer.
Employees
-